Cosman, Felicia <br/><br/>
FRAME Study: The Foundation Effect of Building Bone With 1 Year of Romosozumab Leads to Continued Lower Fracture Risk After Transition to Denosumab.  [electronic resource] 

 -  Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research  07 2018 
 - 1219-1226 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1523-4681 
<br/><br/><label>Standard No.: </label>10.1002/jbmr.3427  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Aged<br/>Antibodies, Monoclonal--therapeutic use<br/>Bone Density<br/>Denosumab--therapeutic use<br/>Fractures, Bone--epidemiology<br/>Humans<br/>Osteogenesis<br/>Risk Factors